To exam the general application of these inhibitors, we also treated allografts of mouse colon cancer CT‐26 cells, mouse breast cancer 4T1 cells, and mouse melanoma B16‐F10 cells with DMSO, DU101 or DU102, which contain 98.3%, 40.1% and 76.6% of the CD133+CD44hi cells (potential CSC markers) respectively.[2] We found that DU101 or DU102 treatment also dramatically regressed tumors but had no effects on mouse body weights in comparison with mice treated with DMSO in the three mouse allograft tumor models (Figure S3a–i, Supporting Information). The gene discussed is PROM1; the disease is breast carcinoma.